Skip to main content

Table 2 Efficacy data at baseline, Week 24, and change from baseline by MDA response, mean (SD)

From: Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity

  Baseline Week 24 Change from BL
MDA-R (n = 152) MDA-NR (n = 322) p MDA-R (n = 152) MDA-NR (n = 322) MDA-R (n = 152) MDA-NR (n = 322) Diff. p
SF-36 PCS 35.8 (9.4) 31.9 (8.9) < 0.001 48.1 (7.1) 35.0 (9.6) 12.3 (9.0) 3.1 (7.8) 9.2 (8.2) < 0.001
SF-36 MCS 49.3 (11.8) 46.8 (12.6) 0.047 53.7 (8.3) 50.5 (11.3) 4.4 (11.5) 3.8 (9.7) 0.7 (10.3) 0.51
EQ-5D-5 L HSI 0.62 (.20) 0.56 (.21) 0.003 0.82 (.14) 0.63 (0.17) 0.20 (0.20) 0.07 (0.20) 0.13 (0.20) < 0.001
EQ-5D VAS 57.5 (21.0) 53.2 (20.3) 0.040 80.0 (16.6) 58.9 (20.3) 22.5 (21.7) 5.7 (22.4) 16.8 (22.2) < 0.001
WPAI-SHP
 % absenteeism 7.8 (20.4)a 6.2 (18.0)b 0.53 4.3 (15.1)a 8.2 (22.7)b −3.5 (20.5)a 2.0 (25.7)b −5.5 (23.9) 0.096
 % presenteeism 33.8 (23.8)c 40.9 (25.6)d 0.061 6.8 (9.0)c 27.7 (22.0)d −27.0 (23.3)c −13.2 (27.0)d −13.74 (25.67) < 0.001
 Overall work impairment 36.0 (25.7)c 42.2 (26.5)d 0.12 9.8 (13.4)c 30.2 (23.8)d −26.2 (25.2)c −12.1 (28.0)d −14.1 (27.0) < 0.001
 % activity impairment non-work 42.2 (25.9)e 52.7 (24.9)f <.001 10.0 (12.0)e 37.9 (24.9)f −32.2 (26.9)e −14.9 (28.4)f −17.4 (27.9) < 0.001
  1. Number of patients with data available where different from total n:an = 84; bn = 142; cn = 82; dn = 134; en = 152; fn = 321
  2. Abbreviations BL = baseline, Diff. = difference, EQ-5D-5 L = European Quality of Life 5 Dimension 5 Level Health Questionnaire, HSI = Health State Index, MCS = mental component summary, MDA = minimal disease activity, PCS = physical component summary, MDA-R = MDA-responder, MDA-NR = MDA-non-responder, SF-36 = 36-Item Short Form Health Survey, VAS = visual analog scale, WPAI-SHP = Work Productivity and Activity Impairment–Specific Health Problem